Skip to main content

ELITE PHARMACEUTICALS INC /NV/

Calidad de datos: 100%
ELTP
OTC Manufacturing Chemicals
$0.38
▲ $0.01 (2.70%)
Cap. Mercado: 409.26 M
Precio
$0.38
Cap. Mercado
409.26 M
Rango del Día
Rango de 52 Semanas
Volumen
Apertura —
Promedio 50D / 200D
Promedio 50D / 200D

Quick Summary

Puntos Clave

Revenue grew 34.90% annually over 5 years — strong growth
Earnings declined -121.46% over the past year
ROE of 61.18% indicates high profitability
Net margin of 30.98% shows strong profitability
Generating 17.24 M in free cash flow
P/E of 9.43 — trading at a low valuation

Crecimiento

Revenue Growth (5Y)
34.90%
Above sector avg (1.82%)
Revenue (1Y)48.42%
Earnings (1Y)-121.46%
FCF Growth (3Y)N/A

Calidad

Return on Equity
61.18%
Above sector avg (-54.44%)
ROIC35.81%
Net Margin30.98%
Op. Margin35.74%

Seguridad

Debt / Equity
N/A
Current Ratio7.34
Interest Coverage440.71

Valoración

PE (TTM)
9.43
Above sector avg (-1.49)
P/B Ratio5.10
EV/EBITDA7.99
Dividend YieldN/A

Historial de Precios

Tendencias Financieras

Comparación con Pares

vs mediana del sector Manufacturing (1385 pares)
Métrica Acción Mediana del Sector
P/E 9.4 -1.5
P/B 5.1 1.6
ROE % 61.2 -54.4
Net Margin % 31.0 -41.5
Rev Growth 5Y % 34.9 1.8
D/E 0.3

Precio Objetivo de Analistas

No hay cobertura de analistas disponible

Estimaciones de Ganancias

Período EPS Est. Ingresos Est. Analistas
FY2026 113.37 M

Sorpresas de Ganancias

Últimos 3 trimestres
Trimestre EPS Est. EPS Real Sorpresa
Q42010 N/A $0.02
Q32010 N/A $0.01
Q22010 N/A -$0.05

All Fundamental Metrics

Growth
Revenue Growth (1Y) 48.42% Revenue Growth (3Y) 56.86%
Earnings Growth (1Y) -121.46% Earnings Growth (3Y) N/A
Revenue Growth (5Y) 34.90% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 140.12 M Net Income (TTM) 43.41 M
ROE 61.18% ROA 35.63%
Gross Margin 51.06% Operating Margin 35.74%
Net Margin 30.98% Free Cash Flow (TTM) 17.24 M
ROIC 35.81% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 7.34
Interest Coverage 440.71 Asset Turnover 1.15
Working Capital 83.60 M Tangible Book Value 74.68 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio 9.43 Forward P/E N/A
P/B Ratio 5.10 P/S Ratio 2.92
PEG Ratio N/A Forward PEG N/A
EV/EBITDA 7.99 Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield 4.21%
Market Cap 409.26 M Enterprise Value 409.26 M
Per Share
EPS (Diluted TTM) 0.04 Revenue / Share 0.13
FCF / Share 0.02 OCF / Share 0.02
EPS CAGR (1Y) -100.00% EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 0.91% FCF Conversion 39.71%
SBC-Adj. FCF N/A Growth Momentum 13.52

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 84.04 M 56.63 M 34.16 M 32.26 M 25.38 M
Net Income -4.31 M 20.11 M 3.56 M 8.90 M 5.09 M
EPS (Diluted) 0.00 0.02 0.00 0.01 0.01
Gross Profit 40.09 M 26.36 M 16.59 M 14.80 M 11.87 M
Operating Income 19.60 M 10.79 M 3.68 M 5.07 M 2.10 M
EBITDA
R&D Expenses 7.96 M 6.88 M 6.20 M 4.05 M 5.11 M
SG&A Expenses
D&A 1.23 M 1.32 M 1.28 M 1.21 M 1.31 M
Interest Expense 128,234.0 588,622.0 1.11 M 191,816.0 259,598.0
Income Tax 4.26 M -19.65 M 424,028.0 -1.74 M

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 96.39 M 83.65 M 40.90 M 35.15 M 26.19 M
Total Liabilities 42.87 M 26.07 M 11.94 M 9.93 M 10.04 M
Shareholders' Equity 53.52 M 57.58 M 28.96 M 25.22 M 16.15 M
Total Debt 1.36 M 1.47 M
Cash & Equivalents 7.11 M 7.83 M 8.54 M 3.19 M
Current Assets 57.74 M 40.01 M 21.51 M 18.86 M 12.19 M
Current Liabilities 11.84 M 13.05 M 7.83 M 6.69 M 5.81 M

Puntuaciones de Estrategias

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches
#11 of 85
52

Actividad Reciente

Entró Capital Light Compounder
Apr 12, 2026